Thursday, December 12, 2019
News on Pathogens and Preparedness
Global Biodefense
No Result
View All Result
  • Featured
  • Pathogens

    Tracing the Ancestral Genome of The Plague

    Aalto Bio Reagents Launches Protein for Detection of Venezuela Equine Encephalitis Virus

    Aalto Bio Reagents Launches Protein for Detection of Venezuela Equine Encephalitis Virus

    African Swine Fever: An Unexpected Threat to the Global Supply of Heparin

    African Swine Fever: An Unexpected Threat to the Global Supply of Heparin

    Bacillus anthracis concept drawing

    Decontamination of Bacillus Spores from Drinking Water Infrastructure

    MERS-CoV: Novel Zoonotic Disease Outbreak a Hard Lesson for Healthcare

    MERS-CoV: Novel Zoonotic Disease Outbreak a Hard Lesson for Healthcare

    red agar plate with cultured bacteria

    Study Shows Virulence of B. pseudomallei Strain in Aerosol Model

    Turns Out, Bat Influenza Can Give You the Flu

    Turns Out, Bat Influenza Can Give You the Flu

    Crimean-Congo Hemorrhagic Fever

    Crimean Congo Countermeasures: Researchers Investigate CCHFV-RDRp

    Yersinia pestis

    Researchers Optimize Novel Hexaplex PCR Assay for Simultaneous Detection of Anthrax and Plague Pathogens

  • Directory
  • Job Board
  • Funding
    • Contracts + Grants
    • Funding Awards
    • Requests for Information
    • Industry News
  • Events
    • All Events
    • Conferences + Meetings
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Headlines
  • Subscribe
  • Featured
  • Pathogens

    Tracing the Ancestral Genome of The Plague

    Aalto Bio Reagents Launches Protein for Detection of Venezuela Equine Encephalitis Virus

    Aalto Bio Reagents Launches Protein for Detection of Venezuela Equine Encephalitis Virus

    African Swine Fever: An Unexpected Threat to the Global Supply of Heparin

    African Swine Fever: An Unexpected Threat to the Global Supply of Heparin

    Bacillus anthracis concept drawing

    Decontamination of Bacillus Spores from Drinking Water Infrastructure

    MERS-CoV: Novel Zoonotic Disease Outbreak a Hard Lesson for Healthcare

    MERS-CoV: Novel Zoonotic Disease Outbreak a Hard Lesson for Healthcare

    red agar plate with cultured bacteria

    Study Shows Virulence of B. pseudomallei Strain in Aerosol Model

    Turns Out, Bat Influenza Can Give You the Flu

    Turns Out, Bat Influenza Can Give You the Flu

    Crimean-Congo Hemorrhagic Fever

    Crimean Congo Countermeasures: Researchers Investigate CCHFV-RDRp

    Yersinia pestis

    Researchers Optimize Novel Hexaplex PCR Assay for Simultaneous Detection of Anthrax and Plague Pathogens

  • Directory
  • Job Board
  • Funding
    • Contracts + Grants
    • Funding Awards
    • Requests for Information
    • Industry News
  • Events
    • All Events
    • Conferences + Meetings
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Headlines
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Debiopharm Progresses in Their Stand Against Drug-Resistant N. gonorrhoeae

by Global Biodefense
8 Nov 2019
Debiopharm Progresses in Their Stand Against Drug-Resistant N. gonorrhoeae

Debiopharm, a Swiss biopharmaceutical company, announced today it has been awarded 2nd phase funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to continue the development of its antibiotic program Debio 1453, leading to a novel FabI inhibitor drug candidate specifically targeting Neisseria gonorrhoeae.

This 9-month extension for up to $1.4 million follows the initial 15-month phase for which up to $2.6 million was awarded in July of 2017, having been successfully completed earlier this year with all objectives met according to plan. The achievement of the targeted milestones during the first phase laid the basis for the CARB-X’s decision to fund the second phase of the research program.  

The Debio 1453 development program concerns a new antibiotic class that targets FabI, an enzyme essential to the growth of certain pathogens such as N. gonorrhoeae. Due to widespread antimicrobial resistance, N. gonorrhoeae creates a serious public health issue, ranking as high priority pathogen by the World Health Organization (WHO) and as an urgent threat by the Centers for Disease Control and Prevention (CDC).1,2  The ongoing research focus of Debiopharm is to optimize lead molecules in order to select a drug candidate which meets the criteria of a Target Product Profile designed to best address the medical need. At the end of the 2nd phase, Debiopharm will select the most suitable compound to enter into clinical trials in uncomplicated gonorrhea caused by drug resistant N. gonorrhoeae.   

“We are delighted and grateful to have been awarded this extended grant from CARB-X,” expressed Thierry Mauvernay, President of Debiopharm. “This continuation of research funding speaks to our antibiotic program’s promising capacity to make a difference in the fight against drug-resistant N. gonorrhoeae.“

N. gonorrhoeae has an expanding history of microbial drug resistance, making previously effective treatments obsolete.3 The CDC reports that N. gonorrhoeae has acquired resistance to practically all classes of antibiotics making it a major global health concern.2 Bacterium-induced/driven Gonorrhea is the second most frequently reported sexually transmitted infection in the world, with an estimated 78 million people infected yearly.3 If left untreated, the infection can potentially lead to other serious conditions including pelvic inflammatory disease and infertility.3

“As a growing variety of super-bugs are showing resistance to existing antibiotics, the time to act is now,” says Terry Finn, Discovery Project Leader at Debiopharm. “This CARB-X award is a great recognition of the progress made in the first phase. It is critical for us to be prepared to avoid a future epidemic of patients with highly resistant N. gonorrhoeae for which there is currently no satisfactory treatment.”

The research is supported by Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by awards from Wellcome Trust, and Germany’s Federal Ministry of Education and Research.

About Debiopharm
Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.

References: 

1. Available at https://apps.who.int/iris/bitstream/handle/10665/246114/9789241549691-eng.pdf

2. Available at https://www.cdc.gov/std/gonorrhea/arg/default.htm  

3. Available at https://www.who.int/news-room/detail/07-07-2017-antibiotic-resistant-gonorrhoea-on-the-rise-new-drugs-needed 

Tags: AwardsBARDADrug Development
Previous Post

Atriva Therapeutics Reports Results of Phase I Clinical Trial for ATR-002 Antiviral

Next Post

Tracing the Ancestral Genome of The Plague

Related Posts

Klebsiella pneumoniae
Antimicrobial Resistance

Inflammatix Wins BARDA Backing for Diagnostic to Rapidly Distinguish Bacterial from Viral Infections

25 Nov 2019
More People in the U.S. Dying from Antibiotic-Resistant Infections than Previously Estimated
Antimicrobial Resistance

More People in the U.S. Dying from Antibiotic-Resistant Infections than Previously Estimated

13 Nov 2019
Carb-X Funds Techulon’s Rapidly Adaptable Nano Therapeutic in Fight Against Drug Resistant Bacteria
Antimicrobial Resistance

Carb-X Funds Techulon’s Rapidly Adaptable Nano Therapeutic in Fight Against Drug Resistant Bacteria

11 Nov 2019
Diagnosing Sepsis in Minutes: Cytovale Raises $15 Million in Financing
Biodetection

Diagnosing Sepsis in Minutes: Cytovale Raises $15 Million in Financing

9 Nov 2019
Genomic Research Viruses
Industry News

Atriva Therapeutics Reports Results of Phase I Clinical Trial for ATR-002 Antiviral

8 Nov 2019
Aalto Bio Reagents Launches Protein for Detection of Venezuela Equine Encephalitis Virus
Biodetection

Aalto Bio Reagents Launches Protein for Detection of Venezuela Equine Encephalitis Virus

27 Oct 2019
Load More
Next Post

Tracing the Ancestral Genome of The Plague

Headlines

  • Artificial Intelligence and Big Data Analytics for Biodefence: Implications for Threat Assessment And Biosurveillance
  • African Swine Fever Kills More Than 20 Wild Boar in Poland
  • Samoa Measles Outbreak: Death Toll Rises To 53, Mostly Children
  • OPCW Defends Syria Attack Conclusions After Document Leaks
  • Osama bin Laden’s “Anthrax Scientist” Freed by Malaysia

Recommended

  • Highly Sensitive Epigenomic Technology Combats Disease
  • Interview: Ambassador Bonnie Jenkins on 8 years of Combating WMD Terrorism
  • There’s No Such Thing as Just-in-Time Healthcare and Public Health Preparedness
  • Threat Detection in Your Pocket
  • Inflammatix Wins BARDA Backing for Diagnostic to Rapidly Distinguish Bacterial from Viral Infections

Featured Partner

  • About
  • Contact
  • Privacy
  • Subscribe

© 2019 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • Pathogens
  • Directory
  • Job Board
  • Funding
    • Contracts + Grants
    • Funding Awards
    • Requests for Information
    • Industry News
  • Events
    • All Events
    • Conferences + Meetings
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Headlines
  • Subscribe

© 2019 Stemar Media Group LLC